PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33728771-6 2021 In addition, treatment with either alectinib or ceritinib modulated the activation of various molecules downstream of RTK signaling and induced caspase-dependent/independent cell death mainly by inhibiting signal transducer and activator of transcription 3 activation in human GBM cells. alectinib 35-44 ret proto-oncogene Homo sapiens 118-121 34803090-4 2021 We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. alectinib 48-57 ret proto-oncogene Homo sapiens 74-77 34803090-4 2021 We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. alectinib 48-57 ret proto-oncogene Homo sapiens 114-117 34803090-5 2021 Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. alectinib 72-81 ret proto-oncogene Homo sapiens 4-7 34225542-1 2021 Introduction: Alectinib is a second-generation inhibitor of anaplastic lymphoma kinase (ALK) and RET. alectinib 14-23 ret proto-oncogene Homo sapiens 97-100 32835580-0 2020 Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. alectinib 29-38 ret proto-oncogene Homo sapiens 105-108 33129112-4 2021 We found that EGF and tumor growth factor alpha (TGFalpha) significantly decreased the antiproliferative activity of the RET inhibitor BLU-667 in CCDC6-RET cells and brigatinib, alectinib and crizotinib in EML4-ALK translocated cells. alectinib 178-187 ret proto-oncogene Homo sapiens 121-124 33569315-0 2021 Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). alectinib 19-28 ret proto-oncogene Homo sapiens 32-35 33569315-0 2021 Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). alectinib 19-28 ret proto-oncogene Homo sapiens 98-101 33569315-10 2021 The primary endpoint was the objective response rate (ORR) in RET inhibitor-naive patients treated with the RD of alectinib. alectinib 114-123 ret proto-oncogene Homo sapiens 62-65 33569315-19 2021 Conclusions: Alectinib exerts limited activity against RET-rearranged NSCLC. alectinib 13-22 ret proto-oncogene Homo sapiens 55-58 32835580-2 2020 Although small molecule agents with RET kinase inhibitory activity such as alectinib, vandetanib, and cabozantinib have been clinically evaluated in RET-fusion-positive NSCLC, an effective monotherapy regimen has not been established. alectinib 75-84 ret proto-oncogene Homo sapiens 36-39 32835580-3 2020 We explored agents to use in combination with alectinib to enhance the antitumor effect of alectinib against RET-fusion cells. alectinib 46-55 ret proto-oncogene Homo sapiens 109-112 32835580-3 2020 We explored agents to use in combination with alectinib to enhance the antitumor effect of alectinib against RET-fusion cells. alectinib 91-100 ret proto-oncogene Homo sapiens 109-112 32835580-13 2020 Combination therapy with alectinib plus the CDK4/6 inhibitor enhanced the antitumor effect against RET-fusion-positive cells in vitro and in vivo. alectinib 25-34 ret proto-oncogene Homo sapiens 99-102 31698333-0 2020 Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. alectinib 0-9 ret proto-oncogene Homo sapiens 57-60 32882995-5 2020 Alectinib is known as an ALK inhibitor but also targets LTK, CHEK2, FLT3, PHKG2, and RET. alectinib 0-9 ret proto-oncogene Homo sapiens 85-88 31698333-1 2020 OBJECTIVES: to report outcomes of four cases of chemo-refractory RET-rearranged non-small cell lung carcinomas (NSCLCs) treated with alectinib in a single center. alectinib 133-142 ret proto-oncogene Homo sapiens 65-68 31698333-2 2020 MATERIALS AND METHODS: we retrospectively assessed and reported the activity and tolerability of alectinib 600 mg twice daily in advanced and chemo-refractory RET-rearranged NSCLC patients treated in a Brazilian institution. alectinib 97-106 ret proto-oncogene Homo sapiens 159-162 31698333-11 2020 CONCLUSION: Although this is a small single center evaluation, alectinib was well tolerated and demonstrated clinical activity against advanced RET-rearranged NSCLCs, suggesting its potential role in this specific subset of malignancies. alectinib 63-72 ret proto-oncogene Homo sapiens 144-147 25349307-0 2014 Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. alectinib 0-9 ret proto-oncogene Homo sapiens 50-53 28629549-0 2017 Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion. alectinib 38-47 ret proto-oncogene Homo sapiens 66-69 29088743-0 2017 In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. alectinib 44-53 ret proto-oncogene Homo sapiens 80-83 29088743-4 2017 Alectinib, an approved ALK inhibitor, is reported to inhibit KIF5B-RET and CCDC6-RET. alectinib 0-9 ret proto-oncogene Homo sapiens 67-70 29088743-4 2017 Alectinib, an approved ALK inhibitor, is reported to inhibit KIF5B-RET and CCDC6-RET. alectinib 0-9 ret proto-oncogene Homo sapiens 81-84 29088743-5 2017 However, the activity of alectinib with respect to RET with other fusion partners is unknown. alectinib 25-34 ret proto-oncogene Homo sapiens 51-54 29088743-6 2017 In the present study, we investigated the effects of alectinib on NCOA4-RET fusion-positive tumor cells in vitro and in vivo. alectinib 53-62 ret proto-oncogene Homo sapiens 72-75 29088743-7 2017 Alectinib inhibited the viability of NCOA4-RET-positive EHMES-10 cells, as well as CCDC6-RET-positive LC-2/ad and TPC-1 cells. alectinib 0-9 ret proto-oncogene Homo sapiens 43-46 29088743-11 2017 These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. alectinib 27-36 ret proto-oncogene Homo sapiens 56-59 29088743-11 2017 These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. alectinib 27-36 ret proto-oncogene Homo sapiens 113-116 29088743-11 2017 These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. alectinib 27-36 ret proto-oncogene Homo sapiens 113-116 29088743-11 2017 These results suggest that alectinib may be a promising RET inhibitor against tumors positive for not only KIF5B-RET and CCDC6-RET, but also NCOA4-RET. alectinib 27-36 ret proto-oncogene Homo sapiens 113-116 28955006-0 2017 Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. alectinib 20-29 ret proto-oncogene Homo sapiens 50-53 28955006-2 2017 Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. alectinib 0-9 ret proto-oncogene Homo sapiens 99-102 28955006-8 2017 CONCLUSION: This is the first study to investigate the safety and preliminary efficacy of alectinib in RET fusion-positive NSCLC patients. alectinib 90-99 ret proto-oncogene Homo sapiens 103-106 28955006-9 2017 If successful, alectinib treatment may lead to substantial and important changes in the management of NSCLC with RET fusion genes. alectinib 15-24 ret proto-oncogene Homo sapiens 113-116 27544060-0 2016 Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. alectinib 21-30 ret proto-oncogene Homo sapiens 43-46 27544060-2 2016 Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. alectinib 0-9 ret proto-oncogene Homo sapiens 94-97 27544060-3 2016 The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported. alectinib 25-34 ret proto-oncogene Homo sapiens 52-55 27544060-4 2016 METHODS: We have described four patients with advanced RET-rearranged NSCLC who were treated with alectinib (600 mg twice daily [n = 3] or 900 mg twice daily [n = 1]) as part of single-patient compassionate use protocols or off-label use of the commercially available drug. alectinib 98-107 ret proto-oncogene Homo sapiens 55-58 27544060-10 2016 A fourth patient who was RET TKI-naive had primary progression while receiving alectinib. alectinib 79-88 ret proto-oncogene Homo sapiens 25-28 27544060-11 2016 CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. alectinib 13-22 ret proto-oncogene Homo sapiens 93-96 27544060-11 2016 CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors. alectinib 13-22 ret proto-oncogene Homo sapiens 147-150 27544060-12 2016 Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies. alectinib 86-95 ret proto-oncogene Homo sapiens 99-102 26798590-0 2015 Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine? alectinib 0-9 ret proto-oncogene Homo sapiens 13-16 26798590-3 2015 Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. alectinib 0-9 ret proto-oncogene Homo sapiens 86-89 26798590-4 2015 Thus alectinib should be further evaluated within clinical trials in patients with RET fusion-positive adenocarcinomas of the lung. alectinib 5-14 ret proto-oncogene Homo sapiens 83-86 29912274-8 2018 A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved. alectinib 84-93 ret proto-oncogene Homo sapiens 28-31 25349307-4 2014 We newly verified that alectinib inhibited RET kinase activity and the growth of RET fusion-positive cells by suppressing RET phosphorylation. alectinib 23-32 ret proto-oncogene Homo sapiens 43-46 25349307-4 2014 We newly verified that alectinib inhibited RET kinase activity and the growth of RET fusion-positive cells by suppressing RET phosphorylation. alectinib 23-32 ret proto-oncogene Homo sapiens 81-84 25349307-4 2014 We newly verified that alectinib inhibited RET kinase activity and the growth of RET fusion-positive cells by suppressing RET phosphorylation. alectinib 23-32 ret proto-oncogene Homo sapiens 81-84 25349307-7 2014 In addition, alectinib showed kinase inhibitory activity against RET gatekeeper mutations (RET V804L and V804M) and blocked cell growth driven by the KIF5B-RET V804L and V804M. alectinib 13-22 ret proto-oncogene Homo sapiens 65-68 25349307-7 2014 In addition, alectinib showed kinase inhibitory activity against RET gatekeeper mutations (RET V804L and V804M) and blocked cell growth driven by the KIF5B-RET V804L and V804M. alectinib 13-22 ret proto-oncogene Homo sapiens 91-94 25349307-7 2014 In addition, alectinib showed kinase inhibitory activity against RET gatekeeper mutations (RET V804L and V804M) and blocked cell growth driven by the KIF5B-RET V804L and V804M. alectinib 13-22 ret proto-oncogene Homo sapiens 91-94 25349307-8 2014 Our results suggest that alectinib is effective against RET fusion-positive tumors. alectinib 25-34 ret proto-oncogene Homo sapiens 56-59 25349307-9 2014 Thus, alectinib might be a therapeutic option for patients with RET fusion-positive NSCLC. alectinib 6-15 ret proto-oncogene Homo sapiens 64-67